Jane Street
ONCT

Jane Street’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Jane Street’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,050
Closed -$195K – 10982
2021
Q2 		$195K Buy
+2,050
New +$243K ﹤0.01% 8852

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Jane Street's ONCT Position: Q4 2023 in Review

Jane Street sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 514 shares — an estimated $3.09K sold.

Jane Street first reported a position in ONCT in Q2 2014 and held it in 8 quarters. The position peaked at $191K in Q1 2021. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

  • Jane Street reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Jane Street sold 514 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.09K.
  • Jane Street first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2014 and held it in 8 quarters.
  • Jane Street's Oncternal Therapeutics, Inc. Common Stock position peaked at $191K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Jane Street's 13F filing for Q4 2023, filed 15 Feb 2024.